As of 2023, Canada recorded hospital discharges for dorsalgia at 8.23 thousand. Forecasted data indicates a gradual increase from 2024, reaching 8.64 thousand by 2028. Year-on-year variations show a consistent rise, with growth rates of approximately 0.96% for 2024, 0.96% for 2025, 1.07% for 2026, and 0.94% for 2027. The five-year compound annual growth rate (CAGR) from 2023 to 2028 is approximately 0.98%.
Future trends to watch for include:
- Potential impact of aging population on dorsalgia cases.
- Advancements in medical treatment reducing hospital stay durations.
- Shifts toward outpatient care models minimizing hospital discharges.
Latest reports
US Autoimmune Disease Market Report- Q1 2025
The US autoimmune disease market in Q1 2025 is experiencing significant shifts driven by advancements in biosimilars, biologics, and innovative therapies. The focus...
China Autoimmune Disease Market Report- Q1 2025
The autoimmune disease market in China has experienced substantial growth in the first quarter of 2025, driven by significant advancements in biopharmaceutical developments,...
Japan Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 witnessed significant developments in the autoimmune disease market in Japan, driven by technological advancements and strategic collaborations that...
Germany Autoimmune Disease Market Report- Q4 2024
The fourth quarter of 2024 marked a significant period for the autoimmune disease market in Germany, driven by advancements in treatment options and...
UK Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 has seen significant developments in the Autoimmune Disease UK market, driven by advancements in personalized medicine, increasing prevalence...
South Korea Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 marks a pivotal period for the Autoimmune Disease Market in South Korea, characterized by significant economic, technological, and...
